Natco Pharma Limited has informed the Exchange regarding Cessation of Mr Dr. Santhan Gopalakrishnan Vaidyanathan as Other of the company w.e.f. September 30, 2025.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has informed the stock exchanges that Dr. Santhan Gopalakrishnan Vaidyanathan, Senior Vice President – Analytical Research & Development (ARD), is superannuating from the company with effect from the close of business hours on September 30, 2025. The disclosure was made under Regulation 30 of SEBI LODR read with Schedule III, covering the required details such as name, reason, and date of cessation. The company has categorised this as a change in Senior Management. No other details such as a brief profile or director relationships were applicable.
This is a routine retirement of a senior executive in the R&D function and is unlikely to have a material impact on the company's operations or share price. Shareholders should watch for any subsequent announcement on a successor for the ARD leadership role.